Bispecific T-Cell Engagers (BiTEs) in Immunotherapy

Abstract

Bispecific T-cell engagers (BiTEs) is a novel subclass of T-cell-engaging bispecific antibodies (bulbs) that are promising for the treatment of cancer. BiTEs direct cytotoxic T-cell activity towards malignant cells, resulting in targeted destruction of tumor cells. This chapter provides an overview of the current landscape of BiTE therapy, highlighting its efficacy in hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) and exploring its potential applications in solid tumors. Additionally, challenges such as immunogenicity, stability, and off-target effects were discussed, alongside ongoing efforts to overcome these obstacles through protein engineering and combination therapies. Future directions in BiTE therapy include optimizing of delivery methods and exploring novel combination strategies. Overall, BiTE therapy represents a promising approach to cancer treatment, with the potential to revolutionize immunotherapy and improve patient outcomes.